Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.
Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Termeyer versuchte, diese Methode auf ein Mehrfachspinnsystem zu übertragen, bei dem mehrere Spinnen befestigt und die Seide von ihnen gleichzeitig abgewickelt werden konnte. Diese Idee wurde erst Ende des 19. Jahrhunderts in Madagaskar aufgegriffen.
Um ebenfalls Spinnenseide direkt aus der Spinne zu gewinnen, entwickelte der Erfinder Daniel Rolt nach eigenen Angaben ein Gerät, mit dem er in zwei Stunden über 5000 Meter Seide von zwei Dutzend Spinnen aufspulen konnte. Er wurde dafür 1830 von der Royal Society of Arts mit einer Silbermedaille ausgezeichnet. Weitere Versuche zur Gewinnung von Spinnenseide unternahm 1863 der auf Folly Island in South Carolina stationierte Chirurg Burt Green Wilder. Bei einem Spaziergang entdeckte er eine große Seidenspinne, die in einem goldfarbenen Netz saß. Wilder fing die Spinne und brachte sie in sein Zelt. Als die Spinne von seinem Ärmel fiel, ergriff er ihren Abseilfaden und wickelte mit einem Federkiel innerhalb von eineinhalb Stunden 137 Meter Spinnenseide auf. Zu diesem Zeitpunkt glaubte Wilder, der Erste zu sein, dem dies gelungen war. Da die Spinnenseide zum Weben zu dünn war, entwickelte er eine Vorrichtung, mit der er von mehreren Spinnen gleichzeitig Seide gewinnen und zu einem dickeren Strang zusammendrehen konnte. Allerdings waren viele Spinnen in dieser Vorrichtung zusammengedrängt und neigten dazu, sich gegenseitig zu fressen. Anhand der gewonnenen Seidenmenge berechnete er, dass er etwa 5000 Spinnen bräuchte, um genügend Material für ein Kleid zu gewinnen. Später entdeckte Wilder Termeyers Schriften, die er übersetzte und 1866 unter dem Titel Researches and Experiments upon Silk from Spider and upon their Reproduction (Untersuchungen und Experimente über Seide von Spinnen und deren Fortpflanzung) veröffentlichte.
Ferner veröffentlichte er eine Reihe von Artikeln über seine Erfahrungen in verschiedenen wissenschaftlichen Zeitschriften. Der französische Jesuitenpater und Spinnenforscher Paul Camboué versuchte Ende des 19. Jahrhunderts erfolglos, eine Spinnenseidenindustrie in Madagaskar aufzubauen. Nephila madagascariensis lieferte bei einer Entnahme zwischen 150 und 600 Meter Seidenfaden, die innerhalb eines Monats fünf- bis sechsmal entnommen werden konnte. Die Gewinnung des Materials war jedoch teuer und konnte nicht mit gewöhnlicher Seide konkurrieren.
Nachdem Madagaskar 1895 von Frankreich erobert wurde, gründete die Kolonialregierung die École Professionnelle in Antananarivo, die von Antoine Jully geleitet wurde. Dort züchtete er in einer Versuchsanlage Seidenspinnen, denen der Faden künstlich entnommen wurde. Nach Camboués Vorbild sollte dort Spinnenseide in großem Maßstab hergestellt werden. Dazu wurde eine Vorrichtung benutzt, mit der zwölf Spinnen gleichzeitig der Faden entnommen und gezwirnt werden konnte. Der Faden wurde auf einer normalen Spinnmaschine später verdoppelt, um einen Faden mit 24 Strängen zu erhalten. Dazu wurden in manchen Monaten über 10.000 Spinnen gesammelt. In einem Jahr wurden so 175.000 Meter 12-fädiges Garn gewonnen. Aus diesem Garn wurden für die Weltausstellung in Paris 1900 Behänge für ein von einheimischen Handwerkern gefertigtes Bett hergestellt, dessen Spinnenseidentuch in der Presse mit begeisterten Worten beschrieben wurde. Der Textilkünstler Simon Peer und der Unternehmer Nicholas Godley begannen 2004 mit der Gewinnung von Spinnenseide aus lebenden Seidenspinnen. In Madagaskar ließen sie mehr als eine Million Seidenspinnen sammeln und gewannen daraus Spinnenseide. Es dauerte acht Jahre, um genug Seide für einen 1,5 Kilogramm schweren goldenen Umhang zu gewinnen, der in verschiedenen Museen ausgestellt wurde. Die Anzahl der benötigten Spinnen entsprach damit der Größenordnung, die Réaumur bereits zu Beginn des 18. Jahrhunderts berechnet hatte. Für das Sammeln der Spinnenseide ist es zudem erforderlich, die Spinne durch Abkühlung zu betäuben.
Sources: de.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.